Patents by Inventor Tsunetaka Ohta
Tsunetaka Ohta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9295627Abstract: The present invention has an object to provide a mouthwash composition for preventing and/or treating periodontal diseases safely and effectively. The present invention solves the above object by providing a mouthwash composition for preventing and/or treating periodontal diseases, characterized in that it comprises, as an effective ingredient(s), one or more members selected from the group consisting of adenosine N1-oxide, 3?-glucosyladenosine N1-oxide, 5?-glucosyladenosine N1-oxide, 5?-adenosine diphosphate N1-oxide, and 5?-adenosine triphosphate N1-oxide but does not contain any saccharide assimilable by periodontal disease bacteria.Type: GrantFiled: December 12, 2012Date of Patent: March 29, 2016Assignee: HAYASHIBARA CO., LTD.Inventors: Keizo Kohno, Emiko Ohashi, Tsunetaka Ohta
-
Publication number: 20140356298Abstract: The present invention has an object to provide a mouthwash composition for preventing and/or treating periodontal diseases safely and effectively. The present invention solves the above object by providing a mouthwash composition for preventing and/or treating periodontal diseases, characterized in that it comprises, as an effective ingredient(s), one or more members selected from the group consisting of adenosine N1-oxide, 3?-glucosyladenosine N1-oxide, 5?-glucosyladenosine N1-oxide, 5?-adenosine diphosphate N1-oxide, and 5?-adenosine triphosphate N1-oxide but does not contain any saccharide assimilable by periodontal disease bacteria.Type: ApplicationFiled: December 12, 2012Publication date: December 4, 2014Inventors: Keizo Kohno, Emiko Ohashi, Tsunetaka Ohta
-
Publication number: 20140094490Abstract: The present invention has an object to provide a novel agent for anti-neurodegenerative diseases and solves the object by providing an agent for anti-neurodegenerative diseases containing, as an effective ingredient, the compound(s) represented by the following General formula 1: wherein in General formula 1, R1 through R3 independently represent a hydrogen atom or an appropriate substituent; Z1 represents a heterocyclic ring and Z2 represents the same or different heterocyclic or aromatic ring as in Z1, wherein the heterocyclic and aromatic rings optionally have a substituent; o represents an integer of 0, 1 or 2; p represents an integer of 0 or 1, with the proviso that p is 1 when o is 0 or 2, and p is 0 when o is 1; R1 and R2 do not exist when o is 0, while, when p is 0, R3 does not exist and the binding between the carbon atom to which R2 binds and Z2 is a single bond; X1? represents an appropriate counter anion and q represents an integer of 1 or 2.Type: ApplicationFiled: December 5, 2013Publication date: April 3, 2014Applicant: KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJOInventors: Hitomi OHTA, Kenji AKITA, Tsunetaka OHTA, Toshio KAWATA, Shigeharu FUKUDA
-
Patent number: 8357782Abstract: The present invention has the first object to provide a monoclonal antibody specific to interferon ? subtype ?8 (IFN?8) and its mutant proteins, the second object to provide a hybridoma capable of producing the monoclonal antibody, the third object to provide a method for detecting the IFN?8 and its mutant proteins by the monoclonal antibody, the fourth object to provide a method for purifying the IFN?8 and its mutant proteins by the monoclonal antibody, and the fifth object to provide a therapeutic agent for treating diseases whose onsets or exacerbation are related with IFN?8.Type: GrantFiled: March 16, 2009Date of Patent: January 22, 2013Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoInventors: Shigeharu Fukuda, Chie Ushio, Harumi Ariyasu, Tohru Kayano, Toshio Ariyasu, Tsunetaka Ohta
-
Patent number: 8187584Abstract: The present invention has an object to provide a tumor necrosis factor mutant protein, particularly, a tumor necrosis factor mutant protein specific to TNF-R1 or TNF-R2; tumor necrosis factor inhibitor; or tumor necrosis factor preparation containing it as an effective ingredient, and the object is solved by providing a tumor necrosis factor mutant protein where one or more amino acid residues selected from the group consisting of 29th, 31st, 32nd, 145th, 146th and 147th, or the group consisting of 84th to 89th from the N-terminal of the amino acid sequence of SEQ ID NO:1 is/are replaced with other amino acid residue(s); a tumor necrosis factor inhibitor; and a tumor necrosis factor preparation containing it as an effective ingredient.Type: GrantFiled: August 8, 2011Date of Patent: May 29, 2012Assignees: Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoInventors: Tadanori Mayumi, Yasuo Tsutsumi, Shinsaku Nakagawa, Tsunetaka Ohta
-
Publication number: 20120035187Abstract: The present invention has an object to provide a novel agent for anti-neurodegenerative diseases and solves the object by providing an agent for anti-neurodegenerative diseases containing, as an effective ingredient, the compound(s) represented by the following General formula 1: wherein in General formula 1, R1 through R3 independently represent a hydrogen atom or an appropriate substituent; Z1 represents a heterocyclic ring and Z2 represents the same or different heterocyclic or aromatic ring as in Z1, wherein the heterocyclic and aromatic rings optionally have a substituent; represents an integer of 0, 1 or 2; p represents an integer of 0 or 1, with the proviso that p is 1 when o is 0 or 2, and p is 0 when o is 1; R1 and R2 do not exist when o is 0, while, when p is 0, R3 does not exist and the binding between the carbon atom to which R2 binds and Z2 is a single bond; X1? represents an appropriate counter anion and q represents an integer of 1 or 2.Type: ApplicationFiled: January 25, 2010Publication date: February 9, 2012Applicant: KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJOInventors: Hitomi Ohta, Kenji Akita, Tsunetaka Ohta, Toshio Kawata, Shigeharu Fukuda
-
Publication number: 20110293555Abstract: The present invention has an object to provide a tumor necrosis factor mutant protein, particularly, a tumor necrosis factor mutant protein specific to TNF-R1 or TNF-R2; tumor necrosis factor inhibitor; or tumor necrosis factor preparation containing it as an effective ingredient, and the object is solved by providing a tumor necrosis factor mutant protein where one or more amino acid residues selected from the group consisting of 29th, 31st, 32nd, 145th, 146th and 147th, or the group consisting of 84th to 89th from the N-terminal of the amino acid sequence of SEQ ID NO:1 is/are replaced with other amino acid residue(s); a tumor necrosis factor inhibitor; and a tumor necrosis factor preparation containing it as an effective ingredient.Type: ApplicationFiled: August 8, 2011Publication date: December 1, 2011Applicants: TADANORI MAYUMI, KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJOInventors: TADANORI MAYUMI, YASUO TSUTSUMI, SHINSAKU NAKAGAWA, TSUNETAKA OHTA
-
Patent number: 7993636Abstract: The present invention has an object to provide a tumor necrosis factor mutant protein, particularly, a tumor necrosis factor mutant protein specific to TNF-R1 or TNF-R2; tumor necrosis factor inhibitor; or tumor necrosis factor preparation containing it as an effective ingredient, and the object is solved by providing a tumor necrosis factor mutant protein where one or more amino acid residues selected from the group consisting of 29th, 31st, 32nd, 145th, 146th and 147th, or the group consisting of 84th to 89th from the N-terminal of the amino acid sequence of SEQ ID NO:1 is/are replaced with other amino acid residue(s); a tumor necrosis factor inhibitor; and a tumor necrosis factor preparation containing it as an effective ingredient.Type: GrantFiled: January 5, 2005Date of Patent: August 9, 2011Assignees: Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoInventors: Tadanori Mayumi, Yasuo Tsutsumi, Shinsaku Nakagawa, Tsunetaka Ohta
-
Publication number: 20110091968Abstract: The present invention has the first object to provide a monoclonal antibody specific to interferon ? subtype ?8 (IFN?8) and its mutant proteins, the second object to provide a hybridoma capable of producing the monoclonal antibody, the third object to provide a method for detecting the IFN?8 and its mutant proteins by the monoclonal antibody, the fourth object to provide a method for purifying the IFN?8 and its mutant proteins by the monoclonal antibody, and the fifth object to provide a therapeutic agent for treating diseases whose onsets or exacerbation are related with IFN?8.Type: ApplicationFiled: March 16, 2009Publication date: April 21, 2011Inventors: Shigeharu Fukuda, Chie Ushio, Harumi Ariyasu, Tohru Kayano, Toshio Ariyasu, Tsunetaka Ohta
-
Publication number: 20090148943Abstract: The present invention has an object to provide a means to effectively enhance the production of cytokines and/or chemokines in mammals. The object is solved by providing an agent for enhancing the production of cytokines and/or chemokines, which comprises, as an effective ingredient, a polypeptide having any one of the amino acid sequences of SEQ ID NOs:1 to 3; a polypeptide having any one of the amino acid sequences of SEQ ID NOs:1 to 3, where one or more amino acids thereof are deleted or replaced with other amino acid(s) and/or one or more amino acids are added thereunto, without substantially losing the biological activity of the polypeptide.Type: ApplicationFiled: November 5, 2008Publication date: June 11, 2009Applicant: Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoInventors: Makoto TAKEUCHI, Takanori Okura, Tomoki Tatefuji, Tetsuya Mori, Chikako Arai, Tsunetaka Ohta, Masashi Kurimoto
-
Publication number: 20070110711Abstract: The present invention has an object to provide a means to effectively enhance the production of cytokines and/or chemokines in mammals. The object is solved by providing an agent for enhancing the production of cytokines and/or chemokines, which comprises, as an effective ingredient, a polypeptide having any one of the amino acid sequences of SEQ ID NOs:1 to 3; a polypeptide having any one of the amino acid sequences of SEQ ID NOs:1 to 3, where one or more amino acids thereof are deleted or replaced with other amino acid(s) and/or one or more amino acids are added thereunto, without substantially losing the biological activity of the polypeptide.Type: ApplicationFiled: October 19, 2006Publication date: May 17, 2007Applicant: KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJOInventors: Makoto Takeuchi, Takanori Okura, Tomoki Tatefuji, Tetsuya Mori, Chikako Arai, Tsunetaka Ohta, Masashi Kurimoto
-
Patent number: 6713618Abstract: Disclosed are a DNA which encodes murine trehalase, a polypeptide expressed by the DNA, and a transgenic- and knockout- animals which have been genetically engineered with the DNA. The DNA comprises a part or the whole of the nucleotide sequence of SEQ ID NO:1.Type: GrantFiled: May 26, 2000Date of Patent: March 30, 2004Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoInventors: Yoshiaki Yanai, Harumi Ariyasu, Tsunetaka Ohta, Masashi Kurimoto
-
Publication number: 20030166596Abstract: Disclosed are a DNA which encodes murine trehalase, a polypeptide expressed by the DNA, and a transgenic- and knockout-animals which have been genetically engineered with the DNA. The DNA comprises a part or the whole of the nucleotide sequence of SEQ ID NO:1.Type: ApplicationFiled: June 25, 2002Publication date: September 4, 2003Applicant: KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJOInventors: Yoshiaki Yanai, Harumi Ariyasu, Tsunetaka Ohta, Masashi Kurimoto
-
Patent number: 5910303Abstract: An agent which contains, as effective ingredients, interferon-.gamma. and a biologically active substance with either or both activities of promoting production of platelets and leukocytes. A small amount of the agent effectively promotes platelet and/or leukocyte production in mammals including humans without causing side effects.Type: GrantFiled: December 12, 1995Date of Patent: June 8, 1999Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoInventors: Kazue Takayama, Akira Harashima, Tsunetaka Ohta, Noboru Izumi, Hiroyoshi Tahata, Masashi Kurimoto
-
Patent number: 5827691Abstract: Disclosed is a novel protein which has a molecular weight of 45,000.+-.5,000 and pI 5.7.+-.0.5 and exhibits cancer metastasis-inhibitory activity. The protein can be prepared by culturing human cells, animal cells and microorganisms capable of producing the protein in a nutrient culture medium while stimulating them with an inducer such as Bacille Calmette-Guerin and lipopolysaccharide.Type: GrantFiled: April 9, 1997Date of Patent: October 27, 1998Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoInventors: Kanso Iwaki, Tsunetaka Ohta, Masashi Kurimoto
-
Patent number: 5731193Abstract: Insertion of IFN-alpha promoters in recombinant DNAs improves their expression efficiencies for useful polypeptides. Expression of such a recombinant DNA in host cells of mammalian origin is artificially controllable by the presence and absence of external stimuli using IFN-alpha inducers. Thus, transformants with such a recombinant DNA readily increase to a maximized cell density with causing neither damages nor extinction due to polypeptides they produce, and subsequent exposure to IFN-alpha inducers allows the proliferated cells to efficiently produce polypeptides with significant glycosylations.Type: GrantFiled: March 31, 1997Date of Patent: March 24, 1998Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoInventors: Tetsuya Mori, Kozo Yamamoto, Tsunetaka Ohta
-
Patent number: 5585474Abstract: Disclosed is a novel protein which has a molecular weight of 45,000.+-.5,000 and pI 5.7.+-.0.5 and exhibits cancer metastasis-inhibitory activity. The protein can be prepared by culturing human cells, animal cells and microorganisms capable of producing the protein in a nutrient culture medium while stimulating them with an inducer such as Bacille Calmette-Gu erin and lipopolysaccharide.Type: GrantFiled: November 13, 1995Date of Patent: December 17, 1996Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoInventors: Kanso Iwaki, Tsunetaka Ohta, Masahi Kurimoto
-
Patent number: 5498697Abstract: Disclosed is a novel protein which has a molecular weight of 45,000.+-.5,000 and pI 5.7.+-.0.5 and exhibits cancer metastasis-inhibitory activity. The protein can be prepared by culturing human cells, animal cells and microorganisms capable of producing the protein in a nutrient culture medium while stimulating them with an inducer such as Bacille Calmette-Guerin and lipopolysaccharide.Type: GrantFiled: September 27, 1993Date of Patent: March 12, 1996Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoInventors: Kanso Iwaki, Tsunetaka Ohta, Masashi Kurimoto